Moderna set to file for US, EU clearance for its coronavirus vaccine

Author: Justin Low | Category: News

Moderna reaffirms that its vaccine is 94.1% effective in primary analysis


  • Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases
  • Vaccine was 100% effective against severe virus cases in trial
  • No new serious safety concerns identified since 16 November trial
  • To apply for US emergency-use authorisation today
  • To apply for EU conditional approval today
  • Expects FDA advisory meeting on 17 December
For bank trade ideas, check out eFX Plus
Another Monday, another dose of vaccine optimism to hit the market. Moderna stocks itself are up 10% in pre-market upon the announcement above but the overall jump in risk trades is more measured, all things considered compared to previous vaccine news.

US 10-year Treasury yields are up 1.6 bps to the highs for the day at 0.854% while the DAX is holding slight gains of around 0.3%. Major currencies are little changed in general with the dollar keeping slightly weaker on the day still.

By continuing to browse our site you agree to our use of cookies, revised Privacy Notice and Terms of Service. More information about cookiesClose